Dr. Javitt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1051 Riverside Dr
Unit 21
New York, NY 10032Phone+1 212-543-5475Fax+1 212-543-5668
Education & Training
- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1986 - 1987
- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1984 - 1986
- Albert Einstein College of MedicineClass of 1983
Certifications & Licensure
- NY State Medical License 1984 - 2025
- MD State Medical License 2009 - 2010
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Safety and Effectiveness of D-serine in Schizophrenia Start of enrollment: 2006 Mar 01
- A Multicenter Study of NAP (AL-108) in Schizophrenia Start of enrollment: 2007 Jul 01
- Sodium Oxybate in Schizophrenia With Insomnia Start of enrollment: 2008 May 01
- Join now to see all
Publications & Presentations
PubMed
- 35 citationsNormal time course of auditory recognition in schizophrenia, despite impaired precision of the auditory sensory ("echoic") memory code.Lucy March, Angel Cienfuegos, Lyra Goldbloom, Walter Ritter, Nelson Cowan
Journal of Abnormal Psychology. 1999-02-01 - 114 citationsAuditory Sensory Dysfunction in Schizophrenia: Imprecision or Distractibility?Esther F. Rabinowicz, Gail Silipo, Robert Goldman, Daniel C. Javitt
Archives of General Psychiatry. 2000-12-01 - 92 citationsAuditory sensory ("echoic") memory dysfunction in schizophreniaRael D. Strous, Nelson Cowan, Walter Ritter, Daniel C. Javitt
The American Journal of Psychiatry. 1995-10-01
Journal Articles
- A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom MechanismsRagy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect
- American Psychiatric Association PublishingCheryl M Corcoran, Daniel C Javitt, National Institutes of Health
- Sensory and Cross-Network Contributions to Response Inhibition in Patients with SchizophreniaDaniel C Javitt, Matthew J Hoptman, ScienceDirect
Press Mentions
- Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy VolunteersMarch 16th, 2023
- CUIMC Update - Sept. 13, 2021September 13th, 2021
- NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. And Big Rock Partners Acquisition Corp (Nasdaq:BRPA)May 25th, 2021
- Join now to see all
Grant Support
- Early Cortical Processing In SchizophreniaNational Institute Of Mental Health2003–2012
- Multimodal Assessment Of Sensory Processing Dysfunction In SchizophreniaNational Institute Of Mental Health2011
- AdministrativeNational Institute Of Mental Health2011
- The Conte Center For Schizophrenia ResearchNational Institute Of Mental Health2010–2011
- The Conte Center For Schizophrenia ResearchNational Institute Of Mental Health2009–2010
- Multimodal Assessment Of Sensory Processing Dysfunction In SchizophreniaNational Institute Of Mental Health2009–2010
- AdministrativeNational Institute Of Mental Health2009–2010
- Sensory Processing Dysfunction In Neuropsychiatric IllnessNational Institute Of Mental Health2008–2010
- Phencyclidine Abuse &Psychosis: Biomedical MechanismsNational Institute On Drug Abuse2007–2010
- Pk/Pd, Dose Finding And Adjunctive Treatment StudiesNational Institute Of Mental Health2005–2009
- D-Serine Treatment Of SchizophreniaNational Institute Of Mental Health2005–2009
- Methods For Sensory Assessment In SchizophreniaNational Institute Of Mental Health2008
- Dopamine In A Primate Model Of Glutamate HypofunctionNational Institute Of Mental Health2004–2008
- Neurophysiological NMDA Dysfunction In SchizophreniaNational Institute Of Mental Health1997–2006
- Phencyclidine Abuse And Psychoses: Biomedical MechanismsNational Institute On Drug Abuse2001–2005
- Mechanisms Of Cognitive Dysfunction In SchizophreniaNational Institute Of Mental Health2001–2005
- Neuroanatomic Basis Of Cognitive ERP Deficit In SchizophFogarty International Center2001–2003
- Treatment Of Negative Symptoms And Cognitive ImpairmentsNational Institute Of Mental Health2000–2003
- High-Density ERP Mapping &FmriNational Center For Research Resources2002
- Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1998–2002
- Phencyclidine Abuse And Psychosis--Biomedical MechanismsNational Institute On Drug Abuse1998–2000
- Intracortical Mechanisms Of COG Dysfunction In SchizophrNational Institute Of Mental Health1997–1999
- Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1996–1997
- Assessment Of Glycine Treatment In SchizophreniaNational Institute Of Mental Health1996–1997
- Phencyclidine Abuse &Psychosis--Biomedical MechanismsNational Institute On Drug Abuse1995
- Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1995
- Early Cortical Processing In SchizophreniaNational Institute Of Mental Health1993–1995
- NMDA Receptors In Processing Contingent Aep GenerationNational Institute Of Mental Health1990–1991
- Phencyclidine Psychopharmacology--SchizophreniaNational Institute Of Mental Health1986–1990
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: